No connection

Search Results

AMRX vs NVST

AMRX
Amneal Pharmaceuticals, Inc.
NEUTRAL
Price
$12.87
Market Cap
$4.11B
Sector
Healthcare
AI Confidence
85%
NVST
Envista Holdings Corporation
NEUTRAL
Price
$25.94
Market Cap
$4.23B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
AMRX
58.5
NVST
92.64
Forward P/E
AMRX
10.87
NVST
16.64
P/B Ratio
AMRX
-57.2
NVST
1.37
P/S Ratio
AMRX
1.36
NVST
1.55
EV/EBITDA
AMRX
10.13
NVST
12.83

Profitability

Gross Margin
AMRX
37.38%
NVST
55.02%
Operating Margin
AMRX
14.06%
NVST
10.74%
Profit Margin
AMRX
2.39%
NVST
1.73%
ROE
AMRX
--
NVST
1.56%
ROA
AMRX
7.32%
NVST
2.78%

Growth

Revenue Growth
AMRX
11.5%
NVST
15.0%
Earnings Growth
AMRX
--
NVST
3146.1%

Financial Health

Debt/Equity
AMRX
450.95
NVST
0.51
Current Ratio
AMRX
2.17
NVST
2.38
Quick Ratio
AMRX
1.39
NVST
1.93

Dividends

Dividend Yield
AMRX
--
NVST
--
Payout Ratio
AMRX
0.0%
NVST
0.0%

AI Verdict

AMRX NEUTRAL

AMRX presents a stark contrast between operational success and financial instability, evidenced by a stable Piotroski F-Score of 4/9 but a critical Debt/Equity ratio of 450.96. While the company shows explosive YoY EPS growth of 75% and a highly attractive Forward P/E of 10.87, its negative book value and a significant gap between the current price ($12.87) and intrinsic value ($1.54) signal high risk. Analyst sentiment remains strongly bullish with a $17 target, yet insider selling and a bearish technical trend suggest caution. The investment thesis relies entirely on continued earnings acceleration to outpace its precarious balance sheet.

Strengths
Explosive YoY EPS growth of 75%
Strong earnings track record with 3/4 beats in the last 4 quarters
Highly attractive Forward P/E of 10.87 compared to trailing 58.50
Risks
Extreme financial leverage with a Debt/Equity ratio of 450.96
Negative shareholders' equity indicated by a Price/Book of -57.20
Severe disconnect between current price ($12.87) and growth-based intrinsic value ($1.54)
NVST NEUTRAL

NVST presents a complex profile with a stable Piotroski F-Score of 4/9 and a significant valuation gap, as the current price of $25.94 far exceeds the Graham Number ($10.93) and Intrinsic Value ($8.26). While the company shows strong short-term price momentum (+61.3% 1Y) and a highly attractive Forward P/E of 16.64, its trailing P/E of 92.64 and razor-thin profit margin of 1.73% indicate a precarious transition period. The bullish analyst consensus is countered by bearish insider sentiment and a 0/100 technical trend, suggesting the market is pricing in a recovery that has not yet fully materialized in the fundamentals.

Strengths
Strong liquidity with a Current Ratio of 2.38 and Quick Ratio of 1.93
Healthy Gross Margin of 55.02% indicating strong product pricing power
Manageable leverage with a Debt/Equity ratio of 0.51
Risks
Severe overvaluation relative to defensive metrics (Graham Number $10.93)
Extremely low net profit margin (1.73%) leaving little room for error
Bearish insider activity and technical trends

Compare Another Pair

AMRX vs NVST: Head-to-Head Comparison

This page compares Amneal Pharmaceuticals, Inc. (AMRX) and Envista Holdings Corporation (NVST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile